{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T21:53:38Z","timestamp":1769032418104,"version":"3.49.0"},"reference-count":21,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Solar urticaria is a rare type of photodermatosis that significantly reduces the quality of life of the subjects affected, with a risk of anaphylaxis should the entire body be exposed to the sun. Patients are forced to modify and limit their normal activities, and since the symptoms are triggered by exposure to sun, which is difficult if not impossible to avoid in everyday life, a safe and effective therapy appears to be essential.<\/jats:p>\n                  <jats:p>Unfortunately, traditional therapies in a discrete number of patients are unable to provide adequate and safe answers.<\/jats:p>\n                  <jats:p>We describe the case of an 18-year-old woman who began to manifest the first symptoms walking under the spring sunshine. A few minutes after sun exposure, itching and burning sensation began, followed immediately by erythema appearance in the photoexposed skin areas.<\/jats:p>\n                  <jats:p>She was treated with non-sedating H1-blocking antihistamines and leukotriene antagonist with no success, so we decided to treat with omalizumab.<\/jats:p>\n                  <jats:p>The satisfactory response after the failure of previous standard therapeutic strategies, confirms the effectiveness of this molecule in the treatment of solar urticaria, which despite what reported in several studies, has not yet been recognized and authorized by the competent Health Authorities in the treatment of this condition.<\/jats:p>","DOI":"10.1515\/med-2019-0042","type":"journal-article","created":{"date-parts":[[2019,6,16]],"date-time":"2019-06-16T06:37:22Z","timestamp":1560667042000},"page":"403-406","source":"Crossref","is-referenced-by-count":11,"title":["Solar urticaria, a disease with many dark sides: is omalizumab the right therapeutic response? Reflections from a clinical case report"],"prefix":"10.1515","volume":"14","author":[{"given":"Massimo","family":"De Martinis","sequence":"first","affiliation":[{"name":"Department of Life, Health and Environmental Sciences, University of L\u2019Aquila, Italy Allergy an Clinical Immunology Unit , AUSL 04 Teramo , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Maddalena","family":"Sirufo","sequence":"additional","affiliation":[{"name":"Department of Life, Health and Environmental Sciences, University of L\u2019Aquila, Italy Allergy an Clinical Immunology Unit , AUSL 04 Teramo , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lia","family":"Ginaldi","sequence":"additional","affiliation":[{"name":"Department of Life, Health and Environmental Sciences, University of L\u2019Aquila, Italy Allergy an Clinical Immunology Unit , AUSL 04 Teramo , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2019,6,7]]},"reference":[{"key":"2026012107370062240_j_med-2019-0042_ref_001","doi-asserted-by":"crossref","unstructured":"Goetze S, Elsner P. Solar Urticaria. J Dtsch Dermatol Ges. 2015 Dec;13(12):1250-1253","DOI":"10.1111\/ddg.12809"},{"key":"2026012107370062240_j_med-2019-0042_ref_002","doi-asserted-by":"crossref","unstructured":"Maurer M, Metz M, Brehler R, Hillen U, Jakob T, Mahler V , Pf\u00f6hler C, Staubach P, Treudler R, Wedi B,Magerl M.Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence. J All Clin Immunol 2018; 141,(2): 638-649","DOI":"10.1016\/j.jaci.2017.06.032"},{"key":"2026012107370062240_j_med-2019-0042_ref_003","doi-asserted-by":"crossref","unstructured":"Arasi S, Crisafulli G, Caminiti L, Guarneri F, Aversa T, Porcaro F, Pajno GB Treatment with omalizumab in a 16-year-old Caucasian girl with refractory solar urticaria. Pediatr Allergy Immunol 2015;26:583-585","DOI":"10.1111\/pai.12413"},{"key":"2026012107370062240_j_med-2019-0042_ref_004","doi-asserted-by":"crossref","unstructured":"Snast I, Kremer N, Lapidoth M, Enk CD, Tal Y, Rosman Y, Confino-Cohen R, Hodak E, Levi A. Omalizumab for the treatment of solar urticarial: case series and systematic review of the literature. J Allergy Clin Immunol Pract 2018; 4: 1198-1204.","DOI":"10.1016\/j.jaip.2018.02.032"},{"key":"2026012107370062240_j_med-2019-0042_ref_005","unstructured":"Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, Bernstein JA, Bindslev-Jensen C, Brzoza Z, BuenseBedrikow R, Canonica GW, Church MK, Craig T, Danilycheva IV, Dressler C, Ensina LF, Gim\u00e9nez-Arnau A, Godse K, Gon\u00e7alo M, Grattan C, Hebert J, Hide M, Kaplan A, Kapp A, Katelaris CH, Kocat\u00fcrk E, Kulthanan K, Larenas-Linnemann D, Leslie TA, Magerl M, Mathelier-Fusade P, Meshkova RY, Metz M, Nast A, Nettis E, Oude-Elberink H, Rosumeck S, Saini SS, S\u00e1nchez-Borges M, Schmid-Grendelmeier P, Staubach P, Sussman G, Toubi E, Vena GA, Vestergaard C, Wedi B, Werner RN, Zhao Z, Maurer M. The EAACI\/GA2LEN\/EDF\/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update. Allergy. 2018 Jul;73(7):1393-1414."},{"key":"2026012107370062240_j_med-2019-0042_ref_006","unstructured":"Badri T., Schlessinger J. Urticaria solar StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018-2017 Jun 27."},{"key":"2026012107370062240_j_med-2019-0042_ref_007","doi-asserted-by":"crossref","unstructured":"Sirufo MM, De Martinis M, Ginaldi L. Omalizumab an effective and safe alternative therapy in severe refractory atopic dermatitis: A case report. Medicine (Baltimore). 2018Jun; 97(24):e10897. doi: 10.1097\/MD.0000000000010897.","DOI":"10.1097\/MD.0000000000010897"},{"key":"2026012107370062240_j_med-2019-0042_ref_008","doi-asserted-by":"crossref","unstructured":"Sirufo MM, Ginaldi L, De Martinis M. Successful treatment with omalizumab in a child with asthma and urticaria: a clinical case report. Front Pediatr 2019 in press","DOI":"10.3389\/fped.2019.00213"},{"key":"2026012107370062240_j_med-2019-0042_ref_009","doi-asserted-by":"crossref","unstructured":"De Martinis M, Sirufo MM, Ginaldi L. A stadium urticaria. Cold Urticaria is still a mostly unknown disease, with a wide spectrum of severity degrees and few therapeutic certainties: is omalizumab one of these? Reflections from a clinical case report. Iran Red Crescent Med J. 2019; 21(1):e84250. doi: 10.5812ircmj.84250.","DOI":"10.5812\/ircmj.84250"},{"key":"2026012107370062240_j_med-2019-0042_ref_010","doi-asserted-by":"crossref","unstructured":"Terrani I, Bircher AJ, Scherer Hofmeier K Solar urticaria induced by visible light: successful treatment with omalizumab. Clin Exp Dermatol 2016;41:890-892","DOI":"10.1111\/ced.12951"},{"key":"2026012107370062240_j_med-2019-0042_ref_011","doi-asserted-by":"crossref","unstructured":"Br\u00fcning JH, Ziemer M, Pemler S, Simon JC, Treudler R. Successful treatment of solar urticaria with omalizumab. J Dtsch Dermatol Ges 2016;14:936-937","DOI":"10.1111\/ddg.13017"},{"key":"2026012107370062240_j_med-2019-0042_ref_012","doi-asserted-by":"crossref","unstructured":"Moncourier M, Assikar S, Matei I, Souyri N, Couture M, Rigot E, Delaum\u00e9nie S, B\u00e9dane C. Visible light-induced solar urticaria is improved by omalizumab. Photodermatol Photoimmunol Photomed 2016;32:314-316","DOI":"10.1111\/phpp.12271"},{"key":"2026012107370062240_j_med-2019-0042_ref_013","doi-asserted-by":"crossref","unstructured":"Ghazanfar MN, Sand C, Thomsen SF. Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients. Br J Dermatol 2016;175:404-6","DOI":"10.1111\/bjd.14540"},{"key":"2026012107370062240_j_med-2019-0042_ref_014","doi-asserted-by":"crossref","unstructured":"Guzelbey O, Ardelean E, Magerl M, Zuberbier T, Maurer M, Metz M. Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy 2008;63:1563-1565","DOI":"10.1111\/j.1398-9995.2008.01879.x"},{"key":"2026012107370062240_j_med-2019-0042_ref_015","doi-asserted-by":"crossref","unstructured":"Levi A, Tal Y, Dranitzki Z, Shalit M, Enk CD. Successful omalizumab treatment of severe solar urticaria in a 6-year-old child. Pediatr Allergy Immunol 2015;26:588-90","DOI":"10.1111\/pai.12441"},{"key":"2026012107370062240_j_med-2019-0042_ref_016","doi-asserted-by":"crossref","unstructured":"Baliu-Piqu\u00e9 C, Aguilera Peir\u00f3 P. Three cases of solar urticaria successfully treated with omalizumab. J Eur Acad Dermatol Venereol 2016;30:704-706","DOI":"10.1111\/jdv.13001"},{"key":"2026012107370062240_j_med-2019-0042_ref_017","doi-asserted-by":"crossref","unstructured":"Aubin F, Avenel-Audran M, Jeanmougin M, Adamski H, Peyron JL, Marguery MC, L\u00e9onard F, Puyraveau M, Viguier M; Soci\u00e9t\u00e9 Fran\u00e7aise de Photodermatologie. Omalizumab in patients with severe and refractory solar urticaria: a phase II multicentric study. J Am Acad Dermatol 2016;74:574-575","DOI":"10.1016\/j.jaad.2015.11.021"},{"key":"2026012107370062240_j_med-2019-0042_ref_018","doi-asserted-by":"crossref","unstructured":"Duchini G, B\u00e4umler W, Bircher AJ, Scherer K. Failure of omalizumab (Xolair\u00ae) in the treatment of a case of solar urticaria caused by ultraviolet A and visible light. Photodermatol Photoimmunol Photomed 2011;27:336-7","DOI":"10.1111\/j.1600-0781.2011.00624.x"},{"key":"2026012107370062240_j_med-2019-0042_ref_019","doi-asserted-by":"crossref","unstructured":"M\u00fcller S, Schempp CM, Jakob T. Failure of omalizumab in the treatment of solar urticaria. J Eur Acad Dermatol Venereol 2016;30:524-525","DOI":"10.1111\/jdv.12922"},{"key":"2026012107370062240_j_med-2019-0042_ref_020","doi-asserted-by":"crossref","unstructured":"Waibel KH, Reese DA, Hamilton RG, Devillez R. Partial improvement of solar urticaria after omalizumab. J Allergy Clin Immunol 2010;125:490-491","DOI":"10.1016\/j.jaci.2009.11.007"},{"key":"2026012107370062240_j_med-2019-0042_ref_021","doi-asserted-by":"crossref","unstructured":"Kowalzick L, Thiel W, C Bielfeld, Ziegler H, Eickenscheidt L. Partial response of solar urticaria to omalizumab therapy. Hautarzt 2017;68:492-6 doi: 10.1007\/s00105-016-3913-0","DOI":"10.1007\/s00105-016-3913-0"}],"container-title":["Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/med\/14\/1\/article-p403.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2019-0042\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2019-0042\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T07:42:12Z","timestamp":1768981332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2019-0042\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,1]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,2,20]]},"published-print":{"date-parts":[[2019,2,20]]}},"alternative-id":["10.1515\/med-2019-0042"],"URL":"https:\/\/doi.org\/10.1515\/med-2019-0042","relation":{},"ISSN":["2391-5463"],"issn-type":[{"value":"2391-5463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,1]]}}}